The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Cytogenetics, TP53 and immunoglobulin genes: exciting areas of research for CLL
Kostas Stamatopoulos, MD, PhD, from The Centre for Research & Technology, Thermi, Greece, talks to us about the importance of networking with laboratories across the world in the study of immunoglobulin genes and TP53 for the treatment of chronic lymphocytic leukemia (CLL). He also notes that there has been interest in the study of cytogenetics over the past few years as there has been increasing evidence that cytogenetics may provide predictive information as to how a patient will respond to novel drugs, which would be useful in personalising medicine for treating CLL patients. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
